4//SEC Filing
Fridriksdottir Hafrun 4
Accession 0001209191-22-008415
CIK 0000818686other
Filed
Feb 9, 7:00 PM ET
Accepted
Feb 10, 4:09 PM ET
Size
12.4 KB
Accession
0001209191-22-008415
Insider Transaction Report
Form 4
Fridriksdottir Hafrun
Executive VP, Global R&D
Transactions
- Sale
Ordinary Shares
2022-02-09$9.06/sh−6,116$55,412→ 51,416.514 total - Exercise/Conversion
Restricted Share Units
2022-02-09−16,121→ 0 total→ Ordinary Shares (16,121 underlying) - Award
Restricted Share Units
2022-02-08+51,488→ 51,488 total→ Ordinary Shares (51,488 underlying) - Exercise/Conversion
Ordinary Shares
2022-02-09+16,121→ 57,532.514 total
Footnotes (7)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.06 to $9.075, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]Restricted share units were granted on February 9, 2018, with 16,120 having vested on each of February 9, 2020 and February 9, 2021 and 16,121 having vested on February 9, 2022.
- [F7]Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001561458
Filing Metadata
- Form type
- 4
- Filed
- Feb 9, 7:00 PM ET
- Accepted
- Feb 10, 4:09 PM ET
- Size
- 12.4 KB